ArticleWorld journal of gastrointestinal oncology2025
Gut microbiota and metabolite changes in metastatic colorectal cancer
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early Postoperative Remodeling of the Exhaled Volatilome Following Curative Surgery for Colorectal Cancer.Journal of clinical medicine · 2026Article
- Microbiota-metabolite signatures in metastatic colorectal cancer: Promise, pitfalls, and the path forward.World journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDistant metastasis causes most colorectal cancer (CRC) deaths. Gut microbiota (GM) dysbiosis and altered metabolites drive metastasis progression, serving as potential diagnostic biomarkers.
aimTo investigate alterations in GM and metabolites between patients with non-metastatic and distant metastatic CRC.
methodsAccording to the inclusion criteria, fresh fecal samples were collected from 14 non-metastatic CRC patients and 15 distant metastatic CRC patients. We performed 16S rRNA sequencing to analyze the composition, diversity, and differential abundance of GM, along with predictive functional profiling of microbial communities. Additionally, all samples underwent liquid chromatography-mass spectrometry (LC-MS)-based untargeted metabolomic sequencing to identify metabolic changes and predict their biological functions.
resultsThe cohort comprised 16 non-metastatic CRC patients (designated as the S group) and 16 distant metastatic CRC patients (designated as the DZ group). Sequence analysis (16S rRNA) identified a total of 35016 operational taxonomic units (OTUs) across both groups (16886 OTUs in the S group; 16270 in the DZ group; 1860 shared between groups). Inter-group microbial diversity analysis revealed notable differences in the β-diversity group (
conclusionGM and microbial metabolites differ significantly between CRC patients with distant metastasis and those without metastasis. Metabolites involved in nucleic acid, alkaloid, and lipid metabolism pathways potentially contribute to distant metastasis in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.